^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Hairy Cell Leukemia
    Drug:Tafinlar (dabrafenib) (BRAF inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    Dabrafenib Is a Safe and Effective Therapy in Relapsed/Refractory Classical Hairy Cell Leukemia

    Published date:
    11/04/2020
    Excerpt:
    ...we have shown that dabrafenib as a single agent or combined with rituximab is a safe and effective therapy in BRAF V600E mutated HCLc, even in those patients with prior time limited duration BRAFi therapy.
    DOI:
    10.1182/blood-2020-137531